StockNews.com initiated coverage on shares of Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Rating) in a research note published on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Several other analysts have also recently issued reports on SPPI. B. Riley cut shares of Spectrum Pharmaceuticals from a buy rating to a neutral rating and cut their price target for the company from $1.50 to $1.00 in a report on Wednesday, November 16th. JMP Securities restated a buy rating and set a $4.00 price target on shares of Spectrum Pharmaceuticals in a research report on Friday, September 23rd. Finally, HC Wainwright lowered their price target on shares of Spectrum Pharmaceuticals from $12.00 to $9.00 and set a buy rating for the company in a research report on Tuesday, September 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of Hold and an average target price of $4.67.
Spectrum Pharmaceuticals Stock Performance
Spectrum Pharmaceuticals stock opened at $0.41 on Monday. Spectrum Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $1.81. The firm has a 50 day moving average price of $0.51 and a 200 day moving average price of $0.79. The company has a market cap of $77.75 million, a price-to-earnings ratio of -0.65 and a beta of 2.04.
Hedge Funds Weigh In On Spectrum Pharmaceuticals
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Spectrum Pharmaceuticals (SPPI)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.